The goal of the Protocol Review and Monitoring System (PRMS) at the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) is to provide systematic internal review and oversight of all cancer-related studies without duplicating traditional peer review.
The Specific Aims of the PRMS are to 1) prioritizing all cancer clinical trials, regardless of source, proposed to be conducted at Wake Forest Baptist Medical Center; 2) reviewing the scientific merit of all investigator-initiated cancer clinical trials proposed to be conducted at Wake Forest Baptist Medical Center; and 3) conducting ongoing review of study accrual and scientific progress of WFBCCC clinical trials. The PRMS process is supported by Disease-Oriented Teams, the Operations Protocol Service, the Protocol Review Committee, and the Clinical Research Oversight Committee. Cancer-related protocols thus are initially developed by Disease-Oriented Team concept review, prioritized within the Disease- Oriented Team portfolio, and then reviewed by the Operations Protocol Service for logistical considerations and the Protocol Review Committee for scientific merit and final prioritization. Monitoring of accrual and scientific progress, including biostatistical reports and interim endpoint analyses, are carried out by the Clinical Research Oversight Committee, with Disease-Oriented Team support. In the most recent grant year, 111 trials were reviewed by the Protocol Review Committee and 280 trials were monitored by the Clinical Research Oversight Committee.
|Xiao, Jiajie; Melvin, Ryan L; Salsbury Jr, Freddie R (2018) Probing light chain mutation effects on thrombin via molecular dynamics simulations and machine learning. J Biomol Struct Dyn :1-18|
|Mao, Chengqiong; Zhao, Yan; Li, Fang et al. (2018) P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. J Control Release 286:289-300|
|Diaz-Garelli, Jose-Franck; Wells, Brian J; Yelton, Caleb et al. (2018) Biopsy Records Do Not Reduce Diagnosis Variability in Cancer Patient EHRs: Are We More Uncertain After Knowing? AMIA Jt Summits Transl Sci Proc 2017:72-80|
|Wang, Mingxuan; Chen, Haiqin; Ailati, Aisikaer et al. (2018) Substrate specificity and membrane topologies of the iron-containing ?3 and ?6 desaturases from Mortierella alpina. Appl Microbiol Biotechnol 102:211-223|
|Westcott, Marlena M; Clemens, Elene A; Holbrook, Beth C et al. (2018) The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells. Vaccine 36:1174-1182|
|Ruiz, Jimmy; Miller, Antonius A; Tooze, Janet A et al. (2018) Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol :|
|Levine, Edward A; Votanopoulos, Konstantinos I; Shen, Perry et al. (2018) A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. J Am Coll Surg 226:434-443|
|Addington, Elizabeth L; Sohl, Stephanie J; Tooze, Janet A et al. (2018) Convenient and Live Movement (CALM) for women undergoing breast cancer treatment: Challenges and recommendations for internet-based yoga research. Complement Ther Med 37:77-79|
|Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162|
|Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681|
Showing the most recent 10 out of 548 publications